Cargando…

Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B

Detalles Bibliográficos
Autores principales:	Schmidt, Manfred, Foster, Graham R., Coppens, Michiel, Thomsen, Hauke, Dolmetsch, Ricardo, Heijink, Liesbeth, Monahan, Paul E., Pipe, Steven W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463188/ https://www.ncbi.nlm.nih.gov/pubmed/37352263 http://dx.doi.org/10.1182/bloodadvances.2023009876

Ejemplares similares

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
por: von Drygalski, Annette, et al.
Publicado: (2022)

Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy
por: Kashiwakura, Yuji, et al.
Publicado: (2023)

Development of an AAV DNA-based synthetic vector for the potential gene therapy of hemophilia in children
por: Shoti, Jakob, et al.
Publicado: (2022)

An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
por: Sun, Junjiang, et al.
Publicado: (2018)

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A
por: Elkouby, Liron, et al.
Publicado: (2021)

Adenovirus‐associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus‐associated virus vector–serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A
por: Stanford, Sophia, et al.
Publicado: (2019)

Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
por: Pipe, Steven
Publicado: (2009)

Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B
por: Rogers, Geoffrey L, et al.
Publicado: (2014)

AAV vector-mediated in vivo reprogramming into pluripotency
por: Senís, Elena, et al.
Publicado: (2018)

Mortality in congenital hemophilia A – a systematic literature review
por: Hay, Charles R. M., et al.
Publicado: (2020)

Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release
por: Lengler, Johannes, et al.
Publicado: (2020)

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
por: Monahan, Paul E., et al.
Publicado: (2021)

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A
por: Klamroth, Robert, et al.
Publicado: (2022)

T Cell-Mediated Immune Responses to AAV and AAV Vectors
por: Ertl, Hildegund C. J.
Publicado: (2021)

AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6
por: Denard, Jérôme, et al.
Publicado: (2018)

Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia
por: Valizadeh, Leila, et al.
Publicado: (2015)

Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors
por: Wang, Qizhao, et al.
Publicado: (2016)

Adenoviral Vectors for Hemophilia Gene Therapy
por: Brunetti-Pierri, N, et al.
Publicado: (2013)

Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy
por: Pipe, Steven W., et al.
Publicado: (2023)

Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer
por: Pipe, Steven, et al.
Publicado: (2019)

Innate Immune Responses to AAV Vectors
por: Rogers, Geoffrey L., et al.
Publicado: (2011)

AAV Vectored Immunoprophylaxis for Filovirus Infections
por: Rghei, Amira D., et al.
Publicado: (2020)

AAV gene therapy vectors in the TMJ
por: Brouxhon, Sabine M., et al.
Publicado: (2022)

Targeting the somatosensory system with AAV9 and AAV2retro viral vectors
por: Skorput, Alexander G. J., et al.
Publicado: (2022)

Prevention of the Musculoskeletal Complications of Hemophilia
por: Rodriguez-Merchan, E. C.
Publicado: (2012)

Transfusion related complications in hemophilia
por: Marwaha, Neelam
Publicado: (2013)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020)

Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
por: Haurigot, Virginia, et al.
Publicado: (2010)

The intersection of vector biology, gene therapy, and hemophilia
por: Lisowski, Leszek, et al.
Publicado: (2021)

Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study
por: van Balen, Erna C., et al.
Publicado: (2022)

Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
por: Zeltner, Nadja, et al.
Publicado: (2010)

Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption
por: Orlowski, Alejandro, et al.
Publicado: (2020)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

AAV Vectors Vaccines Against Infectious Diseases
por: Nieto, Karen, et al.
Publicado: (2014)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B
por: Mingozzi, Federico, et al.
Publicado: (2012)

Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice
por: Lange, Amy M, et al.
Publicado: (2016)

Chimeric Mice Engrafted With Canine Hepatocytes Exhibits Similar AAV Transduction Efficiency to Hemophilia B Dog
por: Shao, Wenwei, et al.
Publicado: (2022)

Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A
por: Long, Brian R., et al.
Publicado: (2021)

Quality of Life in Hemophilia Complicated by Inhibitors
por: Bastani, P, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_67tiho26f0q4nsuelc2qt7gfec